Integrative Multi-Omics in Glaucoma: Defining Mechanistic Axes and Enabling Precision Management

Invest Ophthalmol Vis Sci. 2026 Nov 2;67(13):39. doi: 10.1167/iovs.67.13.39.

ABSTRACT

Glaucoma is increasingly recognized not as a uniform pressure-defined optic neuropathy, but rather as a heterogeneous neurodegenerative disorder driven by interacting genetic, metabolic, mechanical, vascular, inflammatory, and environmental factors. Although genomics, transcriptomics, proteomics, and metabolomics have each yielded important insights, no single omics layer can fully capture the multilevel architecture underlying differences in disease susceptibility, progression, and treatment response. Multi-omics therefore offers a more integrated framework for linking inherited risk, gene regulation, cellular states, protein activity, metabolic vulnerability, and imaging phenotypes to clinically relevant outcomes. This review summarizes recent advances in multi-omics research in glaucoma, spanning genomics, epigenomics and transcriptomics, proteomics, metabolomics and lipidomics, microbiome studies, and emerging approaches such as spatial omics, single-cell multi-omics, radiomics, and exposomics. We further discuss how cross-layer integration, network analysis, Mendelian randomization, imaging genomics, and multimodal artificial intelligence are helping to define convergent pathogenic pathways and clinically relevant molecular subtypes. Particular attention is given to four major pathological axes: extracellular matrix-mechanical stress, mitochondrial-metabolic dysfunction, immune-microbiome dysregulation, and exposure-vascular burden. Despite ongoing challenges in standardization, cohort size, validation, and interpretability, multi-omics is shifting glaucoma research toward mechanism-based stratification and deployable precision care.

PMID:43062417 | DOI:10.1167/iovs.67.13.39